A first test in people of the drug CT-179 for glioblastoma
Official title: OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
Doctors are testing a new drug called CT-179 in people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
Read our full plain-language summary
What the trial team says
This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in patients with recurrent glioblastoma and newly diagnosed MGMT-unmethylated glioblastoma who are eligible to receive radiation therapy following surgery, and to establish the recommended Phase 2 dose.
Key facts
- Registry number
- NCT07739017
- Stage of testing
- Phase 1
- Conditions studied
- Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma
Where it is running
This trial lists 2 sites.
-
Queensland
- Royal Brisbane and Women's Hospital (Herston)
-
Victoria
- Austin Health (Heidelberg)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.